USD
GBP
EUR
Southwest University, in collaboration with Chongqing Xinsaiya Biotechnology Co., Ltd. (hereinafter referred to as Xinsaiya) and the Affiliated Public Health Hospital of Southwest University (Chongqing Public Health Medical Treatment Center, hereinafter referred to as the Public Health Hospital), has successfully developed a novel coronavirus (2019-nCoV) IgM/IgG antibody detection kit. Professor Hu Changhua of the School of Pharmacy at Southwest University led the three parties in technical research. The kit can detect antibody results in patients with the novel coronavirus within 3-10 minutes. Currently, the kit has obtained a test report from the Chongqing Medical Device Quality Inspection Center and has been used to test antibodies in 80 clinically confirmed patients at the Chongqing Public Health Medical Treatment Center, achieving an accuracy rate of 95%. The kit is currently being submitted to relevant departments for approval. The team has also submitted the application through a fast-track process and is awaiting approval, hoping to make it available to those in need as soon as possible to alleviate public concerns.
This reagent kit requires only simple training for operators and is inexpensive, costing only 60-80 yuan per person per test, making it suitable for large-scale screening. The kit requires only a drop of blood and provides visible results within 3 to 15 minutes; it remains accurate even when plasma is diluted 500-1000 times. It is particularly suitable for grassroots facilities such as secondary-level hospitals and township community health centers where specialized testing equipment is scarce, as well as for early screening of large populations.
Compared with the RT-PCR nucleic acid test currently used for diagnosis, this kit is simpler and more efficient, with high sensitivity and specificity. It can effectively solve the problems of lack of professional and technical personnel and limited laboratory conditions in epidemic areas. It can shorten the waiting time for patients, enable timely treatment, and reduce the workload of designated hospitals for epidemic control. It can enable rapid diagnosis of suspected patients and on-site screening of close contacts, promote the forward and downward movement of diagnosis and screening, and effectively prevent cross-infection caused by the intensive examination of the general public in large hospitals. It can quickly triage, block the source of infection, screen out hidden spreaders, and effectively prevent the spread of the epidemic.
Advantages of the New Saia Novel Coronavirus Detection Kit:
1. The instrument is compact and adaptable to various application scenarios, allowing for testing anytime, anywhere;
2. Small sample size and testing of blood samples greatly reduce the risk of infection for medical staff;
3. Easy to operate, requiring no special professionals; ordinary medical staff can operate it after training.
4. Reagents are individually packaged and stored at room temperature;
5. Short testing time, suitable for large-scale screening;
6. It can be used in hospitals ranging from tertiary hospitals to primary care hospitals and community health centers;
7. Large daily sample testing capacity; up to 1,000 samples can be tested per day.